Clinical Trial Detail

NCT ID NCT02584933
Title Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Ceritinib

Age Groups: adult

Additional content available in CKB BOOST